Researchers used a cohort of 1,313 adults with type 1 diabetes, median age of 53, and found that 93% would consider using an adjunct therapy of 200 mg or 400 mg sotagliflozin, with the 400-mg dose as the preferred option, compared with taking insulin alone. The findings in Diabetes Technology & Therapeutics revealed that maintaining A1C levels within a target range, making diabetes management less stressful and keeping daytime blood glucose levels between 70 mg/dL and 180 mg/dL were among the unmet needs considered high priority among patients.
Diabetes patients willing to use adjunct therapies, study finds
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.